Peru Field Safety Notices and Recalls: Execution Sequence and Closure Requirements

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

Regulatory information verified as of October 29, 2026

1. Key takeaways

A Field Safety Notice (Nota de Seguridad en Campo) in Peru is not merely the publication of an announcement; it is an execution chain that runs first to take corrective action, then to notify the competent authority, and finally to issue the market notice and close the loop with verification. Reversing that order exposes the company, in an inspection, to a finding of delayed action on a known risk. The trigger for deciding whether a field safety notice is required should follow the severity of the consequences, and the execution result of a recall must be supported by a verifiable retrieval ledger and effectiveness checks. Regulatory information verified as of October 29, 2026.

2. Legal basis

RegulationReference numberPublication dateProvisions
Norma Sanitaria que Regula las Actividades de Farmacovigilancia y Tecnovigilancia de Productos Farmacéuticos, Dispositivos Médicos y Productos para la SaludR.M. N° 539-2016/MINSA2016-07-27Management of suspected adverse events and risk control measures; submission of assessment conclusions to the competent authority (specific article numbers pending verification; the official publication prevails)
Ley de los Productos Farmacéuticos, Dispositivos Médicos y Productos SanitariosLey N° 294592009-11-26Capítulo XII (control and sanitary vigilance); the authority’s legal basis for control measures
Reglamento para el Registro, Control y Vigilancia Sanitaria de Productos Farmacéuticos, Dispositivos Médicos y Productos SanitariosD.S. N° 016-2011-SA2011-07-27Title IV medical devices; interface between changes and risk control (specific article numbers pending verification; the official publication prevails)
Notificación de sospechas de incidentes de eventos adversos por dispositivos médicosR.D. N° 101-2019-DIGEMID-DG-MINSA2019-06-14Obligated parties and format for incident notification
Decreto Legislativo que optimiza servicios brindados en el marco de la Ley N° 29459Decreto Legislativo N° 13442017-01-06Optimization of service delivery and procedures within the framework of Ley N° 29459

For the specific deadline for issuing a field safety notice and the reference number of a unified template, GRZAN has not verified definitive provisions; in practice the principled requirements of R.M. N° 539-2016/MINSA serve as the baseline, and the official publication of DIGEMID and MINSA prevails.

3. Expert insights

Insight 1 | Corrective action and the field safety notice run on two parallel tracks, with a rigid sequence

The field safety notice answers the question of telling users how to avoid harm; the recall answers the question of taking the risk-bearing product back off the market. The mechanical sequence is: the registration holder first takes immediate risk-blocking actions (suspending shipments, quarantining stock, issuing use warnings), then notifies the competent authority while simultaneously sending written notices to customers. If customers are notified first while the warehouses remain uncontrolled, what the inspector sees is a company that knew of the risk and continued releasing product; conversely, a retrieval without notification leaves users without support until a replacement unit arrives, which will likewise be deemed incomplete correction.

Insight 2 | The order of execution determines the quality of the evidence; closure rests on the retrieval reconciliation rate, not on the number of emails sent

In assessing whether an action was adequate, the competent authority looks at three tables: the shipment traceability table (who received how much), the retrieval reconciliation table (how much came back, whether returned or destroyed on site), and the effectiveness check table (whether receipt was confirmed and end users were informed). Tracking only notification reach rates while ignoring physical reconciliation is the most common evidentiary gap. In our projects we require closure under the identity: shipped quantity equals reconciled quantity, plus quantity confirmed still in use under a restricted-use notice, plus quantity that cannot be traced; the untraceable portion must be supported by a written explanation and improvement measures.

Insight 3 | Domestic and international action tracks must keep a single narrative

The Peruvian market is usually one node in a global recall. If headquarters uses a different description of the risk level or a different product scope in its home market, any conflict between the local written materials and the global line will raise a direct challenge: why is the wording in Peru weaker than in other markets. We require the global and local notices for the same event to be aligned sentence by sentence on three points — the risk description, the applicable scope, and the user instructions — with any divergence documented on file with written justification (for example, a different combination of locally registered models).

4. Practical recommendations

  1. Establish a tiered recall contingency plan that makes shipment suspension and stock quarantine one-click actions, without waiting for headquarters approval.
  2. Use a bilingual template for field safety notices (the Spanish version is the locally official one), containing product identification, the risk description, the immediate actions users must take, the contact person and a receipt mechanism.
  3. Manage the ledger under the identity shipped equals reconciled plus conditionally retained plus untraceable, reconciling line by line.
  4. Sign recall cooperation clauses with the wholesale distributor (Droguería) and laboratory (Laboratorio), fixing their responsibilities for warehouse quarantine, returns and data reporting.
  5. The disposal of retrieved physical product (destruction on site, return shipment, or release after rework) must have a documented basis, with receipt numbers recorded in the ledger.
  6. After the action concludes, produce a closure report containing the reconciliation rate, the risk assessment of the unretrieved portion and the improvement plan, and check its consistency against the global line.

5. Verification checklist

□ The sequence has been followed: quarantine and loss containment first, then notification to the competent authority, then the field safety notice to customers (regulatory information verified as of October 29, 2026).

□ The serious incident was notified within 24 hours; moderate and mild incidents were handled within 20 calendar days.

□ The field safety notice exists in an official Spanish version containing product identification, the risk description, user actions and the receipt mechanism.

□ The shipment traceability table, retrieval reconciliation table and effectiveness check table are complete and mutually consistent.

□ The local materials have been checked against the global recall for consistency in risk description, applicable scope and user instructions.

□ Receipt numbers for physical disposal (destruction, return shipment, release after rework) have been registered.

□ No definitive provision has been verified for the unified template and issuance deadline of field safety notices, and the documents are marked subject to the official publication of DIGEMID and MINSA.

Regulatory information verified as of October 29, 2026.

GRZAN provides medical device registration and post-market compliance support in Peru for manufacturers, importers and authorized representatives. For assistance, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail